Full Breakdown
Progress in Pancreatic Cancer Research and Advocacy in 2025
12/21/2025, 10:58:55 AM
Overview of Key Developments
In 2025, significant advancements were made in the fight against pancreatic cancer, a disease characterized by a five-year survival rate below 20%. Anna Berkenblit, Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network (PanCAN), highlighted the year as one of progress, partnership, and purpose despite challenges such as federal research funding uncertainties. The introduction of PanCAN Research Recovery Grants aimed to protect promising research projects at risk due to funding interruptions, ensuring that scientific momentum continues.
Breakthroughs in Treatment and Research
A pivotal development in 2025 was the completion of enrollment for the RASOLUTE 302 clinical trial, which tests the investigational drug daraxonrasib (RMC-6236) targeting RAS mutations in metastatic pancreatic cancer. This trial is significant as it represents a shift from previously considered 'undruggable' targets to potentially effective treatments. Results from this phase 3 trial are expected in 2026, and daraxonrasib has already received an FDA Priority Review Voucher, underscoring its potential impact.
Additionally, PanCAN's SPARK health data integration platform has transformed research methodologies by allowing faster and more collaborative access to patient data. A partnership with Acurion, Inc. aims to leverage AI to identify actionable biomarkers through digitized pathology images, enhancing therapy selection.
Early Detection Initiatives
Early detection remains a critical focus, with PanCAN's Early Detection Initiative (EDI) enrolling over 8,800 participants to study the relationship between new-onset diabetes and pancreatic cancer. This initiative aims to improve diagnostic methods and is expected to yield data from a one-year follow-up in 2026.
New Treatment Options and Clinical Innovations
In 2025, the FDA approved CABOMETYX (cabozantinib) for patients with pancreatic neuroendocrine tumors (PNETs), expanding treatment options for this rare subtype. The American Society of Clinical Oncology (ASCO) Annual Meeting showcased research on novel therapies, including the use of Tumor Treating Fields (TTFields) in combination with chemotherapy, which showed modest improvements in survival rates for patients with locally advanced pancreatic cancer.
Community Support and Advocacy
PanCAN has also focused on enhancing patient support, launching a partnership with Smart Patients to create an online community for patients and caregivers. This initiative aims to empower individuals by providing a platform for sharing experiences and information.
Looking Ahead
Despite pancreatic cancer being the third leading cause of cancer-related deaths in the United States, 2025 demonstrated promising progress in research, early detection, and patient advocacy. PanCAN remains committed to advocating for increased federal funding to support ongoing research efforts. The collective advancements in diagnostics, treatment options, and community support initiatives signal a hopeful trajectory toward improved outcomes for pancreatic cancer patients.
Verbatim Quotes
- “‘PanCAN’s unwavering commitment to identifying new resources for research and advocacy will ensure that progress continues uninterrupted.” — Howard Crawford, PhD, Henry Ford Health System
- “‘The fusion of SPARK’s real-world data with emerging AI technologies represents a unique opportunity to accelerate innovation in pancreatic cancer care.” — Sudheer Doss, PhD, PanCAN’s Chief Business Officer
- “Together, we move toward a future where early detection is routine, treatments are more effective and better tolerated, and all patients with pancreatic cancer will thrive.” — Anna Berkenblit, Chief Scientific and Medical Officer, PanCAN
